SEC Form 4 Filing for Amylyx Pharmaceuticals, Inc.

This filing details transactions by Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. On September 10, 2026, Mr. Klee sold 29,025 shares of Common Stock for a weighted average price of $32.13, and an additional 1,439 shares for a weighted average price of $33.16. These sales were primarily to cover tax withholding obligations related to the vesting of performance stock units, as indicated by footnote F1. The sales were automatic and not at Mr. Klee's discretion. Following these transactions, Mr. Klee directly owns 3,613,056 shares of Common Stock. Footnotes F2 and F3 provide further detail on the weighted average pricing for the respective sales, with prices ranging from $31.81 to $32.75 and $32.87 to $33.39, respectively.